Apotex Inc. appears to be ahead in the global race to market a biosimilar version of Amgen Inc.’s blockbuster G-CSF product, Neulasta (pegfilgrastim). The company received approval in its native Canada for its version, Lapelga, last month and is now awaiting a decision on its request for a reimbursement listing at a 25% discount to the originator drug.
It is being suggested that the Canadian approval might herald a regulatory green light for biosimilar pegfilgrastims in